Emerald Health Biotechnology España

Emerald Health Biotechnology España (EHBE), formerly known as VivaCell Biotechnology España, is a Spanish biotechnology company specializing in the research and development of novel synthetic cannabinoid-derived therapeutics. Based in Córdoba, the company utilizes a proprietary platform to create new chemical entities (NCEs) from non-psychoactive cannabinoids like cannabidiol (CBD) and cannabigerol (CBG). These molecules are rationally designed to target specific pathways, including PPAR-gamma, CB2 receptors, and the HIF pathway, to treat complex inflammatory, fibrotic, and neurodegenerative diseases. EHBE serves as the primary R&D engine for the Emerald Health group, having developed lead candidates such as EHP-101 and EHP-102, which are being advanced for indications like systemic sclerosis and Parkinson's disease. The company maintains active research collaborations with industry partners like Skye Bioscience to expand the therapeutic potential of its cannabinoid-derived portfolio.